Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Post by Sarb99on Feb 22, 2021 2:19pm
196 Views
Post# 32628004

Few of the point from the Medivolve Webinar

Few of the point from the Medivolve Webinar
  1. Karland deal is cancelled, nothing to talk about. 
  2. Close to 200,000 customers, which means almost 200,000 tests were done and that is a lot of money with a $95 average per test. 
  3. Telehealth and Tele-Diagnostics is the business model for Medivolve after the covid-19 testing slowdown. They already have close to 200,000 customers in the database. 
  4. MEDV going to lead in PCR testing as PCR testings are required for travel and also bring more revenue with $179 per test.
  5. They seem to like offering Saliva PCR testing for $179 at some locations.
  6. Double and triple the number of cubes.
  7. Covixshield is ramping up with some big orders coming.
  8. Investor Relation campaign coming up with creative ways to make people aware.
  9. There were 73,973 COVID-19 tests done at an average sale price of $96 per test in January. There were about 20 collection sites in December, so some tests are done in December. So, with 200,000 customers now, that means they will beat January numbers this month. 

 

<< Previous
Bullboard Posts
Next >>